196 related articles for article (PubMed ID: 28862476)
1. Olaratumab for the treatment of advanced soft tissue sarcoma.
Okuno SH; Maran A; Robinson SI
Expert Rev Anticancer Ther; 2017 Oct; 17(10):883-887. PubMed ID: 28862476
[TBL] [Abstract][Full Text] [Related]
2. Olaratumab for advanced soft tissue sarcoma.
Tobias A; O'brien MP; Agulnik M
Expert Rev Clin Pharmacol; 2017 Jul; 10(7):699-705. PubMed ID: 28447475
[TBL] [Abstract][Full Text] [Related]
3. Olaratumab: A Novel Platelet-Derived Growth Factor Receptor α-Inhibitor for Advanced Soft Tissue Sarcoma.
Andrick BJ; Gandhi A
Ann Pharmacother; 2017 Dec; 51(12):1090-1098. PubMed ID: 28778132
[TBL] [Abstract][Full Text] [Related]
4. Olaratumab in the management of advanced soft tissue sarcoma.
Zobniw CM; Trinh VA; Posey K; Somaiah N
J Oncol Pharm Pract; 2019 Mar; 25(2):442-448. PubMed ID: 30032714
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts.
Cornillie J; Wozniak A; Van Renterghem B; Van Winkel N; Wellens J; Gebreyohannes YK; Debiec-Rychter M; Sciot R; Hompes D; Schöffski P
BMC Cancer; 2019 Jul; 19(1):724. PubMed ID: 31331295
[TBL] [Abstract][Full Text] [Related]
6. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
Tap WD; Jones RL; Van Tine BA; Chmielowski B; Elias AD; Adkins D; Agulnik M; Cooney MM; Livingston MB; Pennock G; Hameed MR; Shah GD; Qin A; Shahir A; Cronier DM; Ilaria R; Conti I; Cosaert J; Schwartz GK
Lancet; 2016 Jul; 388(10043):488-97. PubMed ID: 27291997
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma.
Villalobos VM; Mo G; Agulnik M; Pollack SM; Rushing DA; Singh A; Van Tine BA; McNaughton R; Decker RL; Zhang W; Shahir A; Cronier DM
Cancer Med; 2020 Feb; 9(3):882-893. PubMed ID: 31821732
[TBL] [Abstract][Full Text] [Related]
8. Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model.
Higuchi T; Miyake K; Sugisawa N; Oshiro H; Zhang Z; Razmjooei S; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Cancer Lett; 2019 Jun; 451():122-127. PubMed ID: 30867142
[TBL] [Abstract][Full Text] [Related]
9. Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas.
Vincenzi B; Badalamenti G; Napolitano A; Spalato Ceruso M; Pantano F; Grignani G; Russo A; Santini D; Aglietta M; Tonini G
Crit Rev Oncol Hematol; 2017 Oct; 118():1-6. PubMed ID: 28917265
[TBL] [Abstract][Full Text] [Related]
10. Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy.
Davis EJ; Chugh R
Drug Des Devel Ther; 2017; 11():3579-3587. PubMed ID: 29263653
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma.
Yonemori K; Kodaira M; Satoh T; Kudo T; Takahashi S; Nakano K; Ando Y; Shimokata T; Mori J; Inoue K; Oakley GJ; Sakaguchi S; Tamura K
Cancer Sci; 2018 Dec; 109(12):3962-3970. PubMed ID: 30353601
[TBL] [Abstract][Full Text] [Related]
12. Olaratumab for soft tissue sarcoma.
Teyssonneau D; Italiano A
Expert Opin Biol Ther; 2017 Aug; 17(8):1019-1025. PubMed ID: 28691538
[TBL] [Abstract][Full Text] [Related]
13. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial.
Tap WD; Wagner AJ; Schöffski P; Martin-Broto J; Krarup-Hansen A; Ganjoo KN; Yen CC; Abdul Razak AR; Spira A; Kawai A; Le Cesne A; Van Tine BA; Naito Y; Park SH; Fedenko A; Pápai Z; Soldatenkova V; Shahir A; Mo G; Wright J; Jones RL;
JAMA; 2020 Apr; 323(13):1266-1276. PubMed ID: 32259228
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer.
Mo G; Baldwin JR; Luffer-Atlas D; Ilaria RL; Conti I; Heathman M; Cronier DM
Clin Pharmacokinet; 2018 Mar; 57(3):355-365. PubMed ID: 28620891
[TBL] [Abstract][Full Text] [Related]
15. Olaratumab in soft tissue sarcoma - Current status and future perspectives.
Antoniou G; Lee ATJ; Huang PH; Jones RL
Eur J Cancer; 2018 Mar; 92():33-39. PubMed ID: 29413687
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience.
Striefler JK; Brandes F; Baur A; Pfitzner BM; Kaul D; Rau D; Dörr A; Schmiester M; Koulaxouzidis G; Bullinger L; Märdian S; Flörcken A
BMC Cancer; 2020 Jan; 20(1):68. PubMed ID: 31996176
[TBL] [Abstract][Full Text] [Related]
17. Olaratumab: First Global Approval.
Shirley M
Drugs; 2017 Jan; 77(1):107-112. PubMed ID: 27995580
[TBL] [Abstract][Full Text] [Related]
18. Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α.
Lowery CD; Blosser W; Dowless M; Knoche S; Stephens J; Li H; Surguladze D; Loizos N; Luffer-Atlas D; Oakley GJ; Guo Q; Iyer S; Rubin BP; Stancato L
Clin Cancer Res; 2018 Feb; 24(4):847-857. PubMed ID: 29191969
[No Abstract] [Full Text] [Related]
19. Olaratumab for the treatment of soft tissue sarcoma.
Deshpande HA; Cecchini M; Ni Choileain S; Jones R
Drugs Today (Barc); 2017 Apr; 53(4):247-255. PubMed ID: 28492292
[TBL] [Abstract][Full Text] [Related]
20. Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma.
Jones RL; Mo G; Baldwin JR; Peterson PM; Ilaria RL; Conti I; Cronier DM; Tap WD
Cancer Chemother Pharmacol; 2019 Jan; 83(1):191-199. PubMed ID: 30406840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
